CytoMed Therapeutics Limited (NASDAQ:GDTC) Sees Significant Increase in Short Interest

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 82,200 shares, a growth of 31.1% from the December 15th total of 62,700 shares. Based on an average daily volume of 195,600 shares, the short-interest ratio is currently 0.4 days. Approximately 1.7% of the shares of the stock are sold short.

CytoMed Therapeutics Price Performance

Shares of GDTC stock traded down $0.01 during mid-day trading on Friday, hitting $2.38. The company had a trading volume of 17,375 shares, compared to its average volume of 581,052. The stock’s 50 day moving average price is $2.57 and its 200-day moving average price is $2.13. CytoMed Therapeutics has a 52-week low of $1.20 and a 52-week high of $4.30.

Wall Street Analysts Forecast Growth

Separately, Benchmark reiterated a “speculative buy” rating and issued a $5.00 price target on shares of CytoMed Therapeutics in a research note on Thursday, October 10th.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.